Skip to main content

Caplyta (lumateperone) Disease Interactions

There are 9 disease interactions with Caplyta (lumateperone):

Major

Atypical antipsychotic agents (applies to Caplyta) dementia

Major Potential Hazard, Moderate plausibility.

Elderly patients with dementia- related psychosis treated with antipsychotic drugs are at an increased risk of death, mostly from cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) causes. A causal relationship with antipsychotic use has not been established. In controlled trials, treatment with some atypical antipsychotic drugs was also associated with an increased risk of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, in elderly patients with dementia- related psychosis. These agents are not approved for the treatment of patients with dementia- related psychosis.

Major

Lumateperone (applies to Caplyta) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Avoid the use of lumateperone in patients with moderate or severe hepatic impairment (Child-Pugh B or C) as they experience higher exposure to lumateperone. No dosage adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).

Major

Neuroleptics (applies to Caplyta) tardive dyskinesia

Major Potential Hazard, Moderate plausibility.

Neuroleptic agents may precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years. Elderly patients, particularly women, are most susceptible. Both the risk of developing the syndrome and the likelihood that it will become irreversible increase with the duration and total cumulative dose of neuroleptic therapy administered. However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages. If TD occurs during neuroleptic therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered. TD symptoms may become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years. In patients with preexisting drug-induced TD, initiating or increasing the dosage of neuroleptic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition. The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.

References

  1. Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976): 1-40
  2. Yesavage JA, Tanke ED, Sheikh JI "Tardive dyskinesia and steady-state serum levels of thiothixene." Arch Gen Psychiatry 44 (1987): 913-5
  3. Kopala LC, Honer WG "Schizophrenia and severe tardive dyskinesia responsive to risperidone." J Clin Psychopharmacol 14 (1994): 430-1
  4. Ghelber D, Belmaker RH "Tardive dyskinesia with quetiapine." Am J Psychiat 156 (1999): 796-7
  5. "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.
  6. "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.
  7. "Product Information. Orap Tablets (pimozide)." Gate Pharmaceuticals, Sellersville, PA.
  8. Little JT, Jankovic J "Tardive myoclonus." Mov Disord 2 (1987): 307-11
  9. "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.
  10. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM "Clozapine in tardive dyskinesia - observations from human and animal model studies." J Clin Psychiatry 55 (1994): 102-6
  11. Buzan RD "Risperidone-induced tardive dyskinesia." Am J Psychiatry 153 (1996): 734-5
  12. Yassa R, Mohelsky HE "Tardive dyskinesia in thiothixene treatment ." J Clin Psychiatry 46 (1985): 151
  13. "Product Information. Navane (thiothixene)." Roerig Division, New York, NY.
  14. Branchey MH, Branchey LB, Richardson MA "Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients." Am J Psychiatry 138 (1981): 608-12
  15. "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.
  16. de Leon J, Moral L, Camunas C "Clozapine and jaw dyskinesia: a case report." J Clin Psychiatry 52 (1991): 494-5
  17. Dave M "Clozapine-related tardive dyskinesia." Biol Psychiatry 35 (1994): 886-7
  18. Pakkenberg H, Fog R "Spontaneous oral dyskinesia. Results of treatment with tetrabenazine, pimozide, or both." Arch Neurol 31 (1974): 352-3
  19. Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997): 119-21
  20. "Product Information. Moban (molindone)." Gate Pharmaceuticals, Sellersville, PA.
  21. Meltzer HY, Luchins DJ "Effect of clozapine in severe tardive dyskinesia: a case report." J Clin Psychopharmacol 4 (1984): 286-7
  22. Bruun RD "Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder." Am J Psychiatry 145 (1988): 621-4
  23. Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994): 895-9
  24. Elliott ES, Marken PA, Ruehter VL "Clozapine-associated extrapyramidal reaction." Ann Pharmacother 34 (2000): 615-8
  25. Friedman JH "Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases." Mov Disord 9 (1994): 321-4
  26. Portnoy RA "Hyperkinetic dysarthria as an early indicator of impending tardive dyskinesia." J Speech Hear Disord 44 (1979): 214-9
  27. "Product Information. Haldol (haloperidol)." McNeil Pharmaceutical, Raritan, NJ.
  28. Peabody CA, Brody D, Warner MD "Tardive dyskinesia after low-dose haloperidol." Biol Psychiatry 22 (1987): 111-2
  29. "Product Information. Loxitane C Oral Concentrate (loxapine)" Watson Laboratories Inc, Corona, CA.
  30. Narendran R, Young CM, Pato MT "Possible risperidone-induced tardive dystonia." Ann Pharmacother 34 (2000): 1487-8
  31. Riddle MA, Hardin MT, Towbin KE, et al "Tardive dyskinesia following haloperidol treatment in Tourette's syndrome." Arch Gen Psychiatry 44 (1987): 98-9
  32. Lamberti JS, Bellnier T "Clozapine and tardive dystonia." J Nerv Ment Dis 181 (1993): 137-8
  33. Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995): 1226
  34. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM "Pharmacotherapy: A Pathophysiologic Approach 4th" Stamford, CT: Appleton & Lange (1999):
  35. Herran A, Vazquez-Barquero JL "Tardive dyskinesia associated with olanzapine." Ann Intern Med 131 (1999): 72
  36. "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.
  37. Woerner MG, Sheitman BB, Lieberman JA, Kane JM "Tardive dyskinesia induced by risperidone?" Am J Psychiatry 153 (1996): 843
  38. Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994): 29-35
  39. Dave M "Tardive oculogyric crises with clozapine." J Clin Psychiatry 55 (1994): 264-5
  40. "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.
  41. Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978): 198-217
  42. Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ "Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis." J Clin Psychiatry 48 (1987): 263-7
View all 42 references
Moderate

Antipsychotic agents (applies to Caplyta) aspiration

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Dysphagia

Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs. These drugs should be administered cautiously in patients at risk for aspiration pneumonia.

Moderate

Antipsychotic/neuroleptic agents (applies to Caplyta) seizure

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures, Head Injury, Alcoholism

Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner. This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold. Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.

Moderate

Atypical antipsychotic agents (applies to Caplyta) hematologic abnormalities

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neutropenia

Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents. Patients with preexisting low white blood cell count may be at increased risk. Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended. At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.

Moderate

Atypical antipsychotic agents (applies to Caplyta) hyperglycemia/diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus, Obesity

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents. Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents. It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.

Moderate

Atypical antipsychotic agents (applies to Caplyta) hypotension

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Syncope, Dehydration, Ischemic Heart Disease, Arrhythmias, Diarrhea, Vomiting

The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope. Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke. Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics. Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.

Moderate

Atypical antipsychotic agents (applies to Caplyta) lipid alterations

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hyperlipidemia

Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels. While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile. Before or soon after initiation of antipsychotic medication, obtain a fasting lipid profile at baseline and monitor periodically during treatment.

Caplyta (lumateperone) drug interactions

There are 549 drug interactions with Caplyta (lumateperone)

Caplyta (lumateperone) alcohol/food interactions

There are 4 alcohol/food interactions with Caplyta (lumateperone)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.